What Researchers Did
Researchers conducted a systematic review to assess the efficacy and safety of hyperbaric oxygen therapy (HBOT) for vascular dementia (VaD), used alone or as an adjuvant treatment.
What They Found
Only one randomized controlled trial involving 64 patients was included in the review. This study compared HBOT as an adjuvant to donepezil with donepezil alone. Due to the limited number of included studies, the review could not draw definitive conclusions regarding the efficacy and safety of HBOT for VaD.
What This Means for Canadian Patients
Currently, there is insufficient evidence to recommend hyperbaric oxygen therapy as a treatment for vascular dementia in Canadian patients. Patients should discuss all treatment options with their healthcare providers, focusing on established therapies.
Canadian Relevance
This systematic review does not have a direct Canadian connection.
Study Limitations
The primary limitation of this systematic review is the inclusion of only one small study, which prevents drawing robust conclusions about hyperbaric oxygen therapy for vascular dementia.